MedTrace Logo

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT00324922 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-04-11

No results posted yet for this study

Summary

The primary question of this study is to understand if trimethoprim-sulfamethoxazole (TMP-SMX) is as effective as vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.

Conditions

  • Osteomyelitis
  • Methicillin-resistant Staphylococcus Aureus

Interventions

DRUG

trimethoprim-sulfamethoxazole

trimethoprim/sulfamethoxazole 320/1600 mg po bid

DRUG

vancomycin

1g iv bid

Sponsors & Collaborators

Principal Investigators

  • Timothy H. Dellitt, MD · UW

  • Jeanne Chan, PharmD, MPH · UW

  • Matthew Golden, MD, MPH · UW

  • M. Bradford Henley, MD · UW

  • Jeanne M Marrazzo, MD, MPH · UW

  • Lisa Taitsman, MD · UW

  • Thomas R Hawn, MD, PhD · UW

  • Robert D Harrington, MD · UW

  • Christian Ramers, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-01
Primary Completion
2007-05-01
Completion
2007-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00324922 on ClinicalTrials.gov